Showing 1,098 results

Filters Content type: News, Editors' picks, About HIV Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment

Merck Warns of Victrelis and HIV Protease Inhibitor Interactions

Editor's pick
AIDSMeds
8 February 2012
Hepatitis C treatment

Copy of Merck Warns of Victrelis and HIV Protease Inhibitor Interactions

Editor's pick
Kaiser Daily Global Health Policy Report
8 February 2012
Drug interactions & pharmacokinetics

Combining HCV Med Boceprevir with Boosted HIV Protease Inhibitors Can Lower Drug Levels

Editor's pick
HIVandHepatitis.com
7 February 2012
Hepatitis C treatment

European Study Does Not See Rapid Long-Term Liver Fibrosis in HIV/HCV Coinfected People

Editor's pick
HIVandHepatitis.com
2 February 2012
Hepatitis C treatment

Alcohol Treatment Boosts Hep C Cure Rates Among Drinkers

Editor's pick
AIDSMeds.com
31 January 2012
Hepatitis C treatment side-effects

Common side-effects of hepatitis C protease inhibitors: clinical management advice published

News
20 January 2012
Hepatitis C symptoms & diagnosis

France: Is more frequent monitoring for liver cancer among co-infected people needed?

Editor's pick
CATIE
11 January 2012
Treatment outcomes & life expectancy

Earlier deaths in people with HIV due to drugs, alcohol, co-infections, poorly controlled HIV - not rapid ageing

News
12 December 2011
Hepatitis C treatment

Poor Liver Transplant Outcomes for HIV/HCV Coinfected Patients

Editor's pick
Medscape (requires free registration)
6 December 2011
Hepatitis C treatment

AASLD: Upping Ribavirin Dose Does Not Increase Interferon Effectiveness in HIV/HCV Coinfected Patients

Editor's pick
HIVandHepatitis.com
24 November 2011
Hepatitis & HIV

Hep C deaths outpace HIV; new drugs, services for coinfected

Editor's pick
Bay Area Reporter
23 November 2011
Hepatitis C treatment

Adverse CNS Effects of HCV Treatment Discourage Adherence

Editor's pick
Medscape (requires free registration)
21 November 2011
Hepatitis C treatment

Blood Thinner Reduces Liver Vein Blood Clots, Protects Liver Functioning in People With Cirrhosis

Editor's pick
AIDSMeds
17 November 2011
Hepatitis C treatment

Persistence of very low levels of virus increase risk of relapse after hepatitis C therapy

News
4 November 2011
Hepatitis C treatment

EACS: Predictors of HCV Viral Load in HIV/HCV Coinfected Patients

Editor's pick
HIVandhepatitis.com
27 October 2011
Hepatitis C treatment

Hepatitis C drug boceprevir achieves 70% viral suppression rate in HIV co-infected people within 24 weeks

News
22 October 2011
Hepatitis C treatment

EACS: Antiretroviral Therapy Reduces Liver Fibrosis Progression in HIV/HCV Coinfected People

Editor's pick
HIVandhepatitis.com
20 October 2011
Treatment guidelines

New European HIV treatment guidelines expand treatment recommendations but anticipate possible drug shortages

News
18 October 2011
Hepatitis C treatment

People on methadone can succeed on hepatitis C treatment

News
18 October 2011
Hepatitis C treatment

Gene variant that helps hepatitis C treatment may hinder HIV treatment

News
14 October 2011
Adherence

Hepatitis C Medication Adherence Is an Important Challenge, Study Shows

Editor's pick
AIDSMeds
13 October 2011
Adherence

Copy of Hepatitis C Medication Adherence Is an Important Challenge, Study Shows

Editor's pick
Kaiser Daily Global Health Policy Report
13 October 2011
New & experimental hepatitis C treatment

ICAAC: HCV Drug Telaprevir Shows No Problematic Interactions with Raltegravir

Editor's pick
HIVandhepatitis.com
6 October 2011
Hepatitis C treatment

Hepatitis C patients likely to falter in adherence to treatment regimen over time, Penn study shows

Editor's pick
Eurekalert Medicine & Health
29 September 2011